RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Shenzhen People's Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Shenzhen People's Hospital深圳市人民医院ShenzhenHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05033392, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 79 years; sex: all

    Registered eligibility fields

  2. Confirmed gastric and gastroesophageal junction adenocarcinoma by Gastroscopic biopsy histopathological examination.

    Inclusion criterion 2

  3. Endoscopic ultrasonography and/or enhanced CT/MRI examination confirmed at the stage of cT3/4a Nx or T2 N1-3, M0(AJCC 8th) before randomization.

    Inclusion criterion 3

  4. Patients have received prior therapy with anti-PD-1, anti-PD-L1 or anti-CTLA4 agent.

    Exclusion criterion 4

    Patients with history of autoimmune disease; patients with autoimmune-related hypothyroidism receive stable doses of thyroid hormone replacement therapy Eligible to participate in this study; Type 1 diabetes patients who are controlled after receiving a stable insulin treatment plan are eligible to participate in this study;

    Exclusion criterion 5

    Patients have received systemic immunostimulatory drug therapy (including but not limited to interferon or IL-2) within 4 weeks before enrollment or within 5 half-lives of the drug (whichever is shorter);

    Exclusion criterion 6

  5. The Eastern Cooperative Oncology Group Performance status (ECOG PS) 0-1

    Inclusion criterion 5

  6. Neutrophil count (ANC)≥1.5×l09/L

    Inclusion criterion 7

    Platelet (PLT) ≥80×109/L

    Inclusion criterion 8

    Hemoglobin (Hb) level ≥9.0 g/L

    Inclusion criterion 9

    Total bilirubin level≤1.5×ULN

    Inclusion criterion 10

    Alanine aminotransferase (ALT) level≤3×ULN

    Inclusion criterion 11

    Aspartate aminotransferase (AST) level ≤3×ULN

    Inclusion criterion 12

    International normalized value (INR) or prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≤1.5×ULN

    Inclusion criterion 13

    Serum creatinine (Cr) level ≤1.5×ULN

    Inclusion criterion 14

    Creatinine clearance >50 ml/min (Calculated according to the Cockcroft-Gault formula)

    Inclusion criterion 15

  7. Patients have experienced or currently have other malignancies within 5 years.

    Exclusion criterion 3

    Active infections, including tuberculosis (clinical diagnosis includes clinical history, physical examination and imaging findings, and TB examination according to local medical routines), hepatitis B {known HBV surface antigen (HBsAg) positive, and HBV DNA ≥1000cps/ml}, hepatitis C or human immunodeficiency virus (HIV antibody positive).

    Exclusion criterion 8

    Patients with previous or cured HBV infection (defined as hepatitis B core antibody [anti-HBc] positive and HbsAg negative) are only eligible to participate in this study when HBV DNA is negative (HBV DNA ˂1000cps/ml).

    Exclusion criterion 9

    Patients with positive hepatitis C (HCV) antibodies are only eligible to participate in this study if the polymerase chain reaction shows negative HCV RNA.

    Exclusion criterion 10

  8. Women who are pregnant or breastfeeding.

    Exclusion criterion 13

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05033392, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥18 yeas and ≤79 years. The gender is not limited.
  • Confirmed gastric and gastroesophageal junction adenocarcinoma by Gastroscopic biopsy histopathological examination.
  • Endoscopic ultrasonography and/or enhanced CT/MRI examination confirmed at the stage of cT3/4a Nx or T2 N1-3, M0(AJCC 8th) before randomization.
  • At least 15 unstained sections of formalin-fixed paraffin-embedded tumor tissue sections or fresh tumor tissues can be provided for PD-L1, TMB, tumor infiltrating T lymphocytes, MSI-H/dMMR and EBV detection.
  • The Eastern Cooperative Oncology Group Performance status (ECOG PS) 0-1
  • Adequate bone marrow and organ function meets the following criteria:
  • Neutrophil count (ANC)≥1.5×l09/L
  • Platelet (PLT) ≥80×109/L
  • Hemoglobin (Hb) level ≥9.0 g/L
  • Total bilirubin level≤1.5×ULN
  • Alanine aminotransferase (ALT) level≤3×ULN
  • Aspartate aminotransferase (AST) level ≤3×ULN
  • International normalized value (INR) or prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≤1.5×ULN
  • Serum creatinine (Cr) level ≤1.5×ULN
  • Creatinine clearance >50 ml/min (Calculated according to the Cockcroft-Gault formula)

Exclusion Criteria:

  • Patients with a history of severe hypersensitivity to other monoclonal antibodies or any component of toripalimab injection (JS001).
  • Preoperative pathology diagnosed as squamous cell carcinoma or neuroendocrine tumor.
  • Patients have experienced or currently have other malignancies within 5 years.
  • Patients have received prior therapy with anti-PD-1, anti-PD-L1 or anti-CTLA4 agent.
  • Patients with history of autoimmune disease; patients with autoimmune-related hypothyroidism receive stable doses of thyroid hormone replacement therapy Eligible to participate in this study; Type 1 diabetes patients who are controlled after receiving a stable insulin treatment plan are eligible to participate in this study;
  • Patients have received systemic immunostimulatory drug therapy (including but not limited to interferon or IL-2) within 4 weeks before enrollment or within 5 half-lives of the drug (whichever is shorter);
  • Patients who have undergone allogeneic bone marrow transplantation or solid organ transplantation in the past;
  • Active infections, including tuberculosis (clinical diagnosis includes clinical history, physical examination and imaging findings, and TB examination according to local medical routines), hepatitis B {known HBV surface antigen (HBsAg) positive, and HBV DNA ≥1000cps/ml}, hepatitis C or human immunodeficiency virus (HIV antibody positive).
  • Patients with previous or cured HBV infection (defined as hepatitis B core antibody [anti-HBc] positive and HbsAg negative) are only eligible to participate in this study when HBV DNA is negative (HBV DNA ˂1000cps/ml).
  • Patients with positive hepatitis C (HCV) antibodies are only eligible to participate in this study if the polymerase chain reaction shows negative HCV RNA.
  • There is a serious neurological or mental illness, including dementia and seizures.
  • Suffer from NCI-CTCAE ≥ Grade 2 peripheral neuropathy.
  • Women who are pregnant or breastfeeding.
  • Chronic bowel disease or short bowel syndrome.
  • Those who are deficient in the enzyme dihydropyrimidine dehydrogenase (DPD).
  • Major cardiovascular diseases, such as New York Heart Association heart disease (level II or higher), myocardial infarction within 3 months before randomization, unstable arrhythmia, or unstable angina.
  • Patients with known coronary artery disease, congestive heart failure that does not meet the above criteria, or left ventricular ejection fraction <50% must adopt an optimized and stable medical plan determined by the treating doctor. If necessary, you can consult a cardiologist.

Quoted from ClinicalTrials.gov, NCT05033392, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05033392, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05033392